Uromigos Live 2024 T Cell Directed Therapy Part 1: T Cell Engagers and Cytokine Release Syndrome

At Uromigos Live 2024, a panel moderated by Brian Rini focused on T cell directed therapy in prostate cancer and featured discussion on topics including cytokine release syndrome and new trials analyzing acapatamab, xaluritamig, and tarlatamab. The panel featured guests Michael Morris, MD, and Karen Autio, MD, of Memorial Sloan Kettering Cancer Center, and Tanya Dorff, MD, of City of Hope.
In part one of the session, the panelists discuss T cell engagers, including an introduction and discussion of cytokine release syndrome.